Rhythm reports Q2 2026 IMCIVREE revenue of $71.3 million, strong HO launch uptake
More than 400 patient start forms were filed for IMCIVREE in acquired hypothalamic obesity as RM-718 posted early efficacy data in the same disease.
SEC filing
Latest
1 story